What does INFINITY PHARMA do?

INFINITY PHARMA is a wholesaler in Nazareth-De Pinte. Public Limited, started on 8 December 1976, 1 establishment.

What is the address of INFINITY PHARMA?

The registered office of INFINITY PHARMA is located at Venecoweg 20A, 9810 Nazareth-De Pinte.

Is INFINITY PHARMA still active?

Yes. According to the CBE (29 October 2026) INFINITY PHARMA is active, legal situation “Normale toestand”, started on 8 December 1976.

Is INFINITY PHARMA registered on Peppol?

Yes, INFINITY PHARMA is registered on the Peppol network with ID 0208:0416616681.

What is the enterprise number of INFINITY PHARMA?

The enterprise number of INFINITY PHARMA is BE0416616681.

When was INFINITY PHARMA founded?

INFINITY PHARMA was founded on 8 December 1976.

Who are the directors of INFINITY PHARMA?

According to the 2025 annual accounts, the directors of INFINITY PHARMA are: Rafael PADILLA, Céline Caveye, Cornelia DE JONG, Johan Verlinden.

Is INFINITY PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 8 December 1976; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did INFINITY PHARMA make in 2025?

INFINITY PHARMA recorded a loss after taxes of € 231,419 in financial year 2025.

What is the revenue of INFINITY PHARMA?

In its most recent annual accounts (2025), INFINITY PHARMA reported revenue of € 10,739,695.

How much does an employee at INFINITY PHARMA earn?

The average wage cost per full-time employee at INFINITY PHARMA was € 108,300 in 2025: staff costs of € 1.5 million for 13.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does INFINITY PHARMA have?

According to the 2025 annual accounts, INFINITY PHARMA has 13.6 full-time equivalents (FTE).

Does INFINITY PHARMA have a website?

Yes, INFINITY PHARMA has a website at pharma-pack.be.

INFINITY PHARMA (Public Limited) - Nazareth-De Pinte

Dossier INFINITY PHARMA, printed on 29 October 2026 from databakkes.be/en/0416616681/infinity-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 39 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

INFINITY PHARMA from Nazareth-De Pinte, company number BE0416616681, closed financial year 2025 with a result of € -231,419 after tax. For that financial year INFINITY PHARMA recorded revenue of € 10.7 million and equity of € 16.4 million. Compared with financial year 2024, the result moved from € -822,517 to € -231,419. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.

What it is worth Growing

€ 16.4 million

▲ 30% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -231,419

▲ 72 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 688,336

▲ € 524,292 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 3.1 million.

People and assets in 2025

Full-time equivalents

13.6

▼ 6.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 3.5 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 1.5 million

▼ 28% vs 2024

€ 108,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,717

▲ 14% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 2.2 million

▼ 6% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 83 days on average.

Taxes and wages

€ 182,799

▼ 43% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 7,191,240 Revenue 2022: € 7,191,240 First fiscal year in the series	€ 11,380,729 Revenue 2023: € 11,380,729 ▲ 58% vs 2022 (€ 7,191,240) Favourable step	€ 10,680,049 Revenue 2024: € 10,680,049 ▼ 6% vs 2023 (€ 11,380,729) Unfavourable step	€ 10,739,695 Revenue 2025: € 10,739,695 ▲ 1% vs 2024 (€ 10,680,049) Favourable step	▲ 1%
Profit after taxes	€ -503,430 Profit after taxes 2022: € -503,430 First fiscal year in the series	€ -7,368,330 Profit after taxes 2023: € -7,368,330 ▼ € 6.9 million vs 2022 (€ -503,430) Unfavourable step	€ -822,517 Profit after taxes 2024: € -822,517 ▲ € 6.5 million vs 2023 (€ -7,368,330) Favourable step	€ -231,419 Profit after taxes 2025: € -231,419 ▲ € 591,098 vs 2024 (€ -822,517) Favourable step	▲ € 591,098
Equity	€ 5,815,834 Equity 2022: € 5,815,834 First fiscal year in the series	€ -1,552,496 Equity 2023: € -1,552,496 ▼ € 7.4 million vs 2022 (€ 5,815,834) Unfavourable step	€ 12,633,901 Equity 2024: € 12,633,901 ▲ € 14.2 million vs 2023 (€ -1,552,496) Favourable step	€ 16,402,481 Equity 2025: € 16,402,481 ▲ 30% vs 2024 (€ 12,633,901) Favourable step	▲ 30%
Total debts	€ 47,260,881 Total debts 2022: € 47,260,881 First fiscal year in the series	€ 48,761,409 Total debts 2023: € 48,761,409 ▲ 3% vs 2022 (€ 47,260,881) Unfavourable step	€ 3,337,271 Total debts 2024: € 3,337,271 ▼ 93% vs 2023 (€ 48,761,409) Favourable step	€ 2,409,168 Total debts 2025: € 2,409,168 ▼ 28% vs 2024 (€ 3,337,271) Favourable step	▼ 28%
Cash	€ 147,193 Cash 2022: € 147,193 First fiscal year in the series	€ 276,447 Cash 2023: € 276,447 ▲ 88% vs 2022 (€ 147,193) Favourable step	€ 164,043 Cash 2024: € 164,043 ▼ 41% vs 2023 (€ 276,447) Unfavourable step	€ 688,336 Cash 2025: € 688,336 ▲ € 524,292 vs 2024 (€ 164,043) Favourable step	▲ € 524,292
Retained profit	€ 4,156,863 Retained profit 2022: € 4,156,863 First fiscal year in the series	€ -3,211,467 Retained profit 2023: € -3,211,467 ▼ € 7.4 million vs 2022 (€ 4,156,863) Unfavourable step	€ 3,333,901 Retained profit 2024: € 3,333,901 ▲ € 6.5 million vs 2023 (€ -3,211,467) Favourable step	€ 3,102,481 Retained profit 2025: € 3,102,481 ▼ 7% vs 2024 (€ 3,333,901) Unfavourable step	▼ 7%
Dividend	€ 25,000,000 Dividend 2022: € 25,000,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 25,000,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 44,878,939 Bank debt 2022: € 44,878,939 First fiscal year in the series	€ 44,878,939 Bank debt 2023: € 44,878,939 Unchanged (€ 44,878,939) Unchanged	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 44,878,939) Favourable step	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 53,076,715 Balance sheet total 2022: € 53,076,715 First fiscal year in the series	€ 47,208,913 Balance sheet total 2023: € 47,208,913 ▼ 11% vs 2022 (€ 53,076,715) Unchanged	€ 15,971,172 Balance sheet total 2024: € 15,971,172 ▼ 66% vs 2023 (€ 47,208,913) Unchanged	€ 18,811,649 Balance sheet total 2025: € 18,811,649 ▲ 18% vs 2024 (€ 15,971,172) Unchanged	▲ 18%
Employees (FTE)	9.8 Employees (FTE) 2022: 9.8 First fiscal year in the series	19.1 Employees (FTE) 2023: 19.1 ▲ 9.3 vs 2022 (9.8) Unchanged	19.8 Employees (FTE) 2024: 19.8 ▲ 0.7 vs 2023 (19.1) Unchanged	13.6 Employees (FTE) 2025: 13.6 ▼ 6.2 vs 2024 (19.8) Unchanged	▼ 6.2

Key figures of INFINITY PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to INFINITY PHARMA?

What happened at INFINITY PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 Rafael PADILLA stepped down as director. NBB
2028 Cornelia DE JONG stepped down as director. NBB
2027 Céline Caveye stepped down as director. NBB
Jun 11, 2026 New annual accounts for financial year 2025: loss of € 231,419. Source: NBB ↗
2026 Johan Verlinden stepped down as director. NBB
2023 Rafael PADILLA became a director. NBB
2022 Cornelia DE JONG became a director. NBB
2021 Céline Caveye became a director. NBB

In short

From € 503,430 loss in 2022 to € 231,419 loss in 2025.

Paid € 7,541 in corporate taxes since 2022.

Paid out € 25 million in dividends to the owners in total.

Pays suppliers within 83 days on average.

Original PDFs at the National Bank ↗

Management

INFINITY PHARMA

FAGRON COMPOUNDING SERVICES 100%

FAGRON BELGIUM 100%

ABC Dental and pharmaceutical consultancy

It owns 100% of FAGRON COMPOUNDING SERVICES, 100% of FAGRON BELGIUM and ABC Dental and pharmaceutical consultancy itself.

Directors

According to the 2025 annual accounts

Rafael PADILLA

Director

Also active at: FAGRON BELGIUM, ABC DENTAL AND PHARMACEUTICAL CONSULTANCY, FAGRON CAPITAL, FAGRON COMPOUNDING SERVICES, FAGRON

since 2023 · until 2028

Céline Caveye

Director

since 2021 · until 2027

Cornelia DE JONG

Managing director

Also active at: FAGRON COMPOUNDING SERVICES

since 2022 · until 2028

Johan Verlinden

Director

since 2021 · until 2026

Establishments

Establishment units

Physical locations of this company

Registered office

Venecoweg 20A

9810 Nazareth-De Pinte

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

FAGRON BELGIUM same network

€ 23.8 million revenue · 2025

ABC DENTAL AND PHARMACEUTICAL CONSULTANCY same network

FAGRON CAPITAL same network

FAGRON same network

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS pharma-pack.be

About

Technologies

GitHub PagesGoogle FontsOneTrustPWASlickVarnishlazysizes

Hosting & Email

Email provider

Microsoft 365

Hosting

FASTLY - Fastly, Inc., US

Website info

HTTPS Ja

Languages NL

Features

Webshop Blog Newsletter Client portal Contact page

Security

✓ HTTPS

✓ SPF

✓ DMARC

Network

✓ Load balancing

Details

Company number

0416.616.681

VAT number

BE 0416.616.681

Registered office

Venecoweg 20A, 9810 Nazareth-De Pinte

Names & denominations

INFINITY PHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

8 December 1976

Peppol

Active · Active since 1 Oct 2025

Contact

pharma-pack.be

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

INFINITY PHARMA

Warning lights

Financials

What happened to INFINITY PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions